Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- A typical case of inflammatory breast cancer
- Possible mechanism
- Inflammatory breast cancer facts
- Why is IBC aggressive?
- Epidemiology: risk and protective factors (1)
- Epidemiology: risk and protective factors (2)
- Epidemiology: risk and protective factors (3)
- Challenges
- Standard care of newly diagnosed IBC
- Sad facts about the trimodality approach (1)
- Sad facts about the trimodality approach (2)
- IBC-specific signatures
- IBC intrinsic characteristics
- What we know about IBC
- EGFR as a therapeutic target in IBC
- EGFR-targeted therapy: reversed EMT
- Animal studies of erlotinib
- Inactivating EGFR reduces IBC CSC markers
- COX-2 pathway is linked to EGFR signaling
- Cancer SC mediate clinical outcome in IBC
- COX-2 mediates the CSC phenotype
- Nodal in IBC CSC
- EGFR regulates Nodal signaling in IBC
- Model pathway
- EGFR is a therapeutic target in IBC
- Phase II study of panitumumab
- Targeting tumor-associated macrophages
- The macrophage
- TIG1 promotes IBC progression via Axl kinase
- TP-0903 reduces TN-IBC tumors and M2φ in vivo
- TP-0903 inhibits M2φ cytokines and polarization
- Targeting macrophage
- Rebastinib: a TIE2 inhibitor
- Immune checkpoint inhibitors
- PD-L1/PD1 as Target in IBC
- Immunotherapy in IBC
- JAK-STAT pathway
- Macrophage neutrophil ratio
- Role of statin
- Inflammation and IBC
- Phase II study of adjuvant statin
- IBC intrinsic characteristics
- Panitumumab treatment (1)
- Panitumumab treatment (2)
- Mast cell infiltration
- Mast cells and macrophages
- Conclusion
- Acknowledgements (1)
- Acknowledgements (2)
- Any questions?
Topics Covered
- Introduction to inflammatory breast cancer
- Epidemiology of IBC
- Approaches to treatment of IBC
- Molecular analysis of IBC
- The contribution of microenvironmental factors to the aggressiveness of IBC
- Targeting the cancer microenvironmental factors for treating IBC
- The involvement of macrophages and mast cells in the aggressiveness of IBC
Talk Citation
Ueno, N.T. (2020, May 31). Targeting the cancer microenvironment: inflammatory breast cancer management [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/ECEW7941.Export Citation (RIS)
Publication History
Financial Disclosures
- Naoto Ueno has received funding for his work from the State of Texas funding for research of rare and aggressive breast cancers, Celgene, Merck, Amgen, IPC, Genentech, the National Cancer Institute, Komen for the Cure, and the Breast Cancer Research Foundation.
Targeting the cancer microenvironment: inflammatory breast cancer management
Published on May 31, 2020
38 min
A selection of talks on Oncology
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Naoto Ueno.
I am the Executive Director of Morgan
Welch Inflammatory Breast Cancer Research
Program and
Clinic at MD Anderson Cancer Center.
Today I am going to be talking about
"Targeting Cancer Microenvironment",
particularly for
inflammatory breast cancer management.
0:19
This picture depicts typical appearance
of inflammatory breast cancer.
You can see that right breast is engorged
and there is some slight redness.
And you can see the edema.
A 'peau d'orange' changes are also
another typical change that we see.
The question remains,
what are the mechanistic underlying things
contributing to the cause
of this erythema?
0:44
One of the mechanism that people
have been speculating is that,
from the pathology perspective,
there is a tumor emboli in the dermal
lymphatic channel that causes
skin inflammatory changes.
The question remains that whether
these inflammatory changes are simply
immunological or true inflammation,
and that remains unknown.
This review paper actually talks
about different aspects of potential
causes of inflammatory breast cancer.
1:15
So inflammatory breast cancer is one
of the most aggressive breast cancer.
It represents about 2 to 4% of
breast cancer in the United States.
When you look from the perspective of the
breast cancer deaths in the United States,
it represents about 10%.
Now in North and Western Africa,
such as Egypt, Tunisia,
Senegal, it is a major health issue,
because inflammatory breast
cancer represents about 15%.
Also, the limited healthcare access
results in a higher rate of breast
cancer mortality.
The appearance I have shown you before,
commonly is misdiagnosed as mastitis,
because it looks inflamed and
it is probably appropriate to say
that this appears like mastitis.
So therefore treating with antibiotics
is a first round of clinical practice.
But once the antibiotic is not working,
we need to consider that there is a
possibility of inflammatory breast cancer.
The other thing that we have to remember
is that this type of breast cancer does
not always have a mass.
If you do a mammogram, roughly 30 to
40% of women will not have any mass,
and that's where the confusion starts,
because our general
expectation about breast cancer is
that you're supposed to see a mass.
Hide